http://www.businessweek.com/investor/content/may2006/pi20060515_699075.htmBoston Scientific (BSX) : Ups to 3 STARS (hold) from 2 STARS (sell)Analyst: Robert GoldThe shares are down this morning, after Boston Scientific issued an advisory to physicians about possible battery failure and malfunctions in certain defibrillator devices that were part of the operations of recently acquired Guidant. The number of failures seems to us mimimal relative to the number of implantations. We do not believe the development will impact the company's defibrillator sales, and think it acted appropriately. We are upping our 12-month target price by $1 to $21.
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.